Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9281136 | 0.81 | — | — | |
| SCHEMBL8608379 | 0.68 | MAOA (0.33) | — | |
| SCHEMBL1078392 | 0.68 | — | — | |
| SCHEMBL8857064 | 0.65 | CYP19A1 (0.30) | — | |
| SCHEMBL27526976 | 0.65 | MAPT (0.30) | — | |
| SCHEMBL527137 | 0.64 | — | — | |
| SCHEMBL6487916 | 0.64 | MAOA (0.31) | — | |
| SCHEMBL18551254 | 0.64 | — | — | |
| SCHEMBL9900722 | 0.64 | — | — | |
| SCHEMBL23181453 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103183654-B | Separation purification preparation process for activated monomers of celery seeds | UNIVTAISHAN MEDICAL | 2014-11-05 | — | — | CN | claimed |
| CN-101978980-B | Szechuan lovage rhizome total phthalide extract | SHENZHEN TAIKANG PHARMACY CO LTD | 2012-07-25 | — | — | CN | claimed |
| CN-101978980-A | Szechuan lovage rhizome total phthalide extract | SHENZHEN TAIKANG PHARMACY CO LTD | 2011-02-23 | — | — | CN | claimed |
| CN-100506225-C | Pharmaceutical use, medicine composition and preparation process of angelica oil components | JIANGXI QINGFENG PHARMACEUTICA (CN) | 2009-07-01 | — | — | CN | claimed |
| CN-1810241-A | Pharmaceutical use, medicine composition and prepn process of angelica oil components | JIANGXI QINGFENG PHARMACEUTICA (CN) | 2006-08-02 | — | — | CN | claimed |
| CN-113549038-B | Polysubstituted isobenzofuran compound and application thereof | 常州大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-106727601-A | One kind treats pleuritic medicine | 郑州欧印数字科技有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-105213370-A | Application of phthalide compound | EVERFRONT BIOTECH INC | 2016-01-06 | — | — | CN | disclosed |
| CN-104547781-A | Traditional Chinese medicine agentia for treating arteriosclerosis and preparation of thereof | WANG SHIGUO | 2015-04-29 | — | — | CN | disclosed |
| CN-103183654-A | Separation purification preparation process for activated monomers of celery seeds | UNIVTAISHAN MEDICAL | 2013-07-03 | — | — | CN | disclosed |
| CN-101978980-B | Szechuan lovage rhizome total phthalide extract | SHENZHEN TAIKANG PHARMACY CO LTD | 2012-07-25 | — | — | CN | disclosed |
| CN-102283197-A | Application of o-hydroxybenzoic acid lactone compounds to alleviation of poisoning of amide herbicides on paddy rice | — | 2011-12-21 | — | — | CN | disclosed |
| EP-1973877-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| CN-101071130-A | Method for establishing quality standard fingerprint spectrum of Chinese material medica | CHINA GUANGZHOU ANALYSIS AND T (CN) | 2007-11-14 | — | — | CN | disclosed |
| WO-2007084450-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| CN-1810241-A | Pharmaceutical use, medicine composition and prepn process of angelica oil components | JIANGXI QINGFENG PHARMACEUTICA (CN) | 2006-08-02 | — | — | CN | disclosed |
| US-20060014735-A1 | Use of urea variants as affinity ligands | CYTIVA BIOPROCESS R&D AB (SE) | 2006-01-19 | — | — | US | disclosed |
| WO-2004039843-A1 | IMMUNOGLOBULIN G BINDING POCKET | AMERSHAM BIOSCIENCES AB (SE) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004039765-A1 | USE OF UREA VARIANTS AS AFFINITY LIGANDS | AMERSHAM BIOSCIENCES AB (SE) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003082310-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OR PREVENTION OF IL-1 MEDIATED DISORDERS | GENERAL NUTRITION INVESTMENT COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014735-A1 | Use of urea variants as affinity ligands | IGLV6-57, FCGR2A, FCGR3B | CHRNB2 2662/4885CHRNB4 2148/4885CHRNA3 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.